rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-210-217rsp-2707Research ArticleФОРУМ МОЛОДЫХ УЧЕНЫХYOUNG SCIENTISTS FORUMРегистры псориатического артрита. Обзор литературыRegisters of psoriatic arthritis. Literature reviewКолтаковаА. Д.KoltakovaA. D.

младший научный сотрудник лаборатории диагностики и инновационных методов лечения псориатического артрита (научный руководитель – д.м.н. Т.В. Коротаева) 

115522, Москва, Каширское шоссе, 34

34A, Kashirskoe Shosse, Moscow, 115522

koltakova.a.d@gmail.comФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияА V.A. Nasonova Research Institute of RheumatologyRussian Federation201914052019572210217Copyright © Колтакова А.Д., 20192019Колтакова А.Д.Koltakova A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2707

Наблюдательные когортные исследования являются эффективным способом изучения хронических заболеваний, в том числе псориатического артрита, в клинической практике. Один из инструментов, обеспечивающих проведение таких исследований, – регистры, в которых аккумулируются данные, связанные с различными аспектами заболевания и фармакотерпией. В настоящем обзоре представлена информация об основных регистрах больных псориатическим артритом.

Observational cohort investigations are an effective way to study chronic diseases, including psoriatic arthritis, in clinical practice. One of the tools to support such research is registers that collect data related to various aspects of the disease and pharmacotherapy. This review provides information on the main registers of patients with psoriatic arthritis.

псориатический артритпсориазрегистркогортные наблюдательные исследованияpsoriatic arthritispsoriasisregistercohort observational studiesReferencesShah K, Paris M, Mellars L, et al. Real-world burden of comorboditiesin US patients with psoriatic arthritis. RMD Open. 2017;3:e000588. doi: 10.1136/rmdopen-2017-000588Shah K, Paris M, Mellars L, et al. Real-world burden of comorboditiesin US patients with psoriatic arthritis. RMD Open. 2017;3:e000588. doi: 10.1136/rmdopen-2017-000588Gladman DD, Farewell VT. Longitudinal cohort studies. J Rheumatol Suppl. 2005;72:30-2.Gladman DD, Farewell VT. Longitudinal cohort studies. J Rheumatol Suppl. 2005;72:30-2.Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user's guide. 2 nd ed. Rockville (MD): Agency for Healthcare Research and Quality; 2010. http://www.ncbi.nlm.nih.gov/books/NBK49444Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user's guide. 2 nd ed. Rockville (MD): Agency for Healthcare Research and Quality; 2010. http://www.ncbi.nlm.nih.gov/books/NBK49444Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis. 2004;63:ii13-7.18.Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis. 2004;63:ii13-7.18.Zink A, Askling J, Dixon WG, et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis. 2009;68:1240-6. doi: 10.1136/ard.2008.091926Zink A, Askling J, Dixon WG, et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis. 2009;68:1240-6. doi: 10.1136/ard.2008.091926Gladman DD, Coates LC, Jadon DR, et al. The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. J Rheumatol Suppl. 2018;94:26-9. doi: 10.3899/jrheum.180132Gladman DD, Coates LC, Jadon DR, et al. The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. J Rheumatol Suppl. 2018;94:26-9. doi: 10.3899/jrheum.180132Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis -clinical and laboratory analysis of 220 patients. Q J Med. 1987;62:127-41.Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis -clinical and laboratory analysis of 220 patients. Q J Med. 1987;62:127-41.Bond SJ, Farewell VT, Schentag CT, et al. Predictors for radiological damage in psoriatic arthritis. Results from a single center. Ann Rheum Dis. 2007;66:370-6. doi: 10.1136/ard.2006.056457Bond SJ, Farewell VT, Schentag CT, et al. Predictors for radiological damage in psoriatic arthritis. Results from a single center. Ann Rheum Dis. 2007;66:370-6. doi: 10.1136/ard.2006.056457Gladman DD, Hing EN, Schentag CT, et al. Remission in psoriatic arthritis. J Rheumatol. 2001;28:1045-8.Gladman DD, Hing EN, Schentag CT, et al. Remission in psoriatic arthritis. J Rheumatol. 2001;28:1045-8.Coates LC, Cook R, Lee KA, et al. Frequency, predictors and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res. 2010;62:970-6. doi: 10.1002/acr.20162Coates LC, Cook R, Lee KA, et al. Frequency, predictors and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res. 2010;62:970-6. doi: 10.1002/acr.20162Brockbank J, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis (PsA): a marker for disease severity? Ann Rheum Dis. 2005;62:188-90. doi: 10.1136/ard.2003.018184Brockbank J, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis (PsA): a marker for disease severity? Ann Rheum Dis. 2005;62:188-90. doi: 10.1136/ard.2003.018184Hanly J, Russell ML, Gladman DD. Psoriatic spondyloarthropathy: a long term prospective study. Ann Rheum Dis. 1988;47:386-93. doi: 10.1136/ard.47.5.386Hanly J, Russell ML, Gladman DD. Psoriatic spondyloarthropathy: a long term prospective study. Ann Rheum Dis. 1988;47:386-93. doi: 10.1136/ard.47.5.386Chandran V, Barrett J, Schentag CT, et al. Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol. 2009;36:2744-50. doi: 10.3899/jrheum.090412Chandran V, Barrett J, Schentag CT, et al. Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol. 2009;36:2744-50. doi: 10.3899/jrheum.090412Chandran V, Tolusso DC, Cook RJ, et al. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J Rheumatol. 2010 Apr;37(4):809-15. doi: 10.3899/jrheum.091059Chandran V, Tolusso DC, Cook RJ, et al. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J Rheumatol. 2010 Apr;37(4):809-15. doi: 10.3899/jrheum.091059Long JA, Husted JA, Matthews DE, et al. The relationship between patient satisfaction with health and clinical measures of function and disease status in patients with PsA. J Rheumatol. 2000;27:958-66.Long JA, Husted JA, Matthews DE, et al. The relationship between patient satisfaction with health and clinical measures of function and disease status in patients with PsA. J Rheumatol. 2000;27:958-66.Husted JA, Tom BD, Schentag CT, et al. Occurrence and correlates of fatigue in psoriatic arthritis (PsA). Ann Rheum Dis. 2009;68:1553-8. doi: 10.1136/ard.2008.098202Husted JA, Tom BD, Schentag CT, et al. Occurrence and correlates of fatigue in psoriatic arthritis (PsA). Ann Rheum Dis. 2009;68:1553-8. doi: 10.1136/ard.2008.098202Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009 Jul;68(7):1131-5. doi: 10.1136/ard.2008.094839Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009 Jul;68(7):1131-5. doi: 10.1136/ard.2008.094839Gladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41(6):1103-10. doi: 10.1002/1529-0131(199806)41:6<1103::AIDART18>3.0.CO;2-NGladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41(6):1103-10. doi: 10.1002/1529-0131(199806)41:6<1103::AIDART18>3.0.CO;2-NBruce IN, Schentag C, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol. 2000;6(1):6-9. doi: 10.1097/00124743-200002000-00001Bruce IN, Schentag C, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol. 2000;6(1):6-9. doi: 10.1097/00124743-200002000-00001Johnson SR, Schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis. 2005;64(5):770-2. doi: 10.1136/ard.2004.031286Johnson SR, Schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis. 2005;64(5):770-2. doi: 10.1136/ard.2004.031286Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol. 1995;22(2):241-5.Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol. 1995;22(2):241-5.Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008;35(3):469-71.Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008;35(3):469-71.Chandran V, Siannis F, Rahman P,et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37(7):1508-12. doi: 10.3899/jrheum.091311Chandran V, Siannis F, Rahman P,et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37(7):1508-12. doi: 10.3899/jrheum.091311Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol. 1992;19(11):1724-6.Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol. 1992;19(11):1724-6.Mader R, Gladman DD, Long J, et al. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med. 1995;18(2):139-43.Mader R, Gladman DD, Long J, et al. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med. 1995;18(2):139-43.Rahman P, Gladman DD, Zhou Y, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998;25(10):1957-61.Rahman P, Gladman DD, Zhou Y, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998;25(10):1957-61.Lee JC, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7(3):160-5. doi: 10.1097/00124743-200106000-00005Lee JC, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7(3):160-5. doi: 10.1097/00124743-200106000-00005Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004;63(2):156-61. doi: 10.1136/ard.2003.006775Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004;63(2):156-61. doi: 10.1136/ard.2003.006775Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatol (Oxford). 2010;49(7):1399-405. doi: 10.1093/rheumatology/keq105Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatol (Oxford). 2010;49(7):1399-405. doi: 10.1093/rheumatology/keq105Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford). 2011;50(1):25-31. doi: 10.1093/rheumatology/keq262Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford). 2011;50(1):25-31. doi: 10.1093/rheumatology/keq262Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33(9):834-9. doi: 10.1093/rheumatology/33.9.834Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33(9):834-9. doi: 10.1093/rheumatology/33.9.834Korendowych E, Dixey J, Cox B, et al. The influence of the HLADRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol. 2003;30(1):96-101.Korendowych E, Dixey J, Cox B, et al. The influence of the HLADRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol. 2003;30(1):96-101.McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42(6):778-83. doi: 10.1093/rheumatology/keg217McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42(6):778-83. doi: 10.1093/rheumatology/keg217Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a single-center study from the UK. J Rheumatol. 2010 Oct;37(10):2141-4. doi: 10.3899/jrheum.100034Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a single-center study from the UK. J Rheumatol. 2010 Oct;37(10):2141-4. doi: 10.3899/jrheum.100034Mease PJ, Karki C, Palmer JB, et al. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017;69(11):1692-9. doi: 10.1002/acr.23249Mease PJ, Karki C, Palmer JB, et al. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017;69(11):1692-9. doi: 10.1002/acr.23249Mease PJ, Karki C, Palmer JB, et al. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017;44(8):1151-8. doi: 10.3899/jrheum.160963Mease PJ, Karki C, Palmer JB, et al. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017;44(8):1151-8. doi: 10.3899/jrheum.160963Mease PJ, Palmer JB, Litman HJ, et al. Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis – Descriptive Analysis from the Corrona Psoriatic Arthritis / Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheum. 2016;68.Mease PJ, Palmer JB, Litman HJ, et al. Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis – Descriptive Analysis from the Corrona Psoriatic Arthritis / Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheum. 2016;68.Mease PJ, Palmer JB, Liu M, et al. Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis / Spondyloarthritis Registry. J Rheumatol. 2018;45(10):1389-96. doi: 10.3899/jrheum.171094Mease PJ, Palmer JB, Liu M, et al. Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis / Spondyloarthritis Registry. J Rheumatol. 2018;45(10):1389-96. doi: 10.3899/jrheum.171094Labitigan M, Bahce-Altuntas A, Kremer JM, et al. Rates and Clustering of Abnormal Lipids, Obesity, and Diabetes in Psoriatic Arthritis Compared with Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2014;66(4):600-7. doi: 10.1002/acr.22185Labitigan M, Bahce-Altuntas A, Kremer JM, et al. Rates and Clustering of Abnormal Lipids, Obesity, and Diabetes in Psoriatic Arthritis Compared with Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2014;66(4):600-7. doi: 10.1002/acr.22185Shrestha A, Bahce-Altuntas A, Mowrey W, et el. Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis. Semin Arthritis Rheum. 2016;46(3):286-90. doi: 10.1016/j.semarthrit.2016.05.011Shrestha A, Bahce-Altuntas A, Mowrey W, et el. Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis. Semin Arthritis Rheum. 2016;46(3):286-90. doi: 10.1016/j.semarthrit.2016.05.011Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S96-S99.Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S96-S99.Curtis JR, Beukelman T, Onofrei A, et al. Elevated Liver Enzyme Tests Among Rheumatoid Arthritis and Psoriatic Arthritis Patients treated with Methotrexate and/or Leflunomide. Ann Rheum Dis. 2010;69(1):43-7. doi: 10.1136/ard.2008.101378Curtis JR, Beukelman T, Onofrei A, et al. Elevated Liver Enzyme Tests Among Rheumatoid Arthritis and Psoriatic Arthritis Patients treated with Methotrexate and/or Leflunomide. Ann Rheum Dis. 2010;69(1):43-7. doi: 10.1136/ard.2008.101378Mease PJ, Collier DH, Saunders KC, et al. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181Mease PJ, Collier DH, Saunders KC, et al. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181Harrold LR, Stolshek BS, Rebello S, et al. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017;36(4):895-901. doi: 10.1007/s10067-017-3593-xHarrold LR, Stolshek BS, Rebello S, et al. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017;36(4):895-901. doi: 10.1007/s10067-017-3593-xMease PJ, Karki C, Liu M, et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open. 2018;4(1):e000638. doi: 10.1136/rmdopen-2017-000638Mease PJ, Karki C, Liu M, et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open. 2018;4(1):e000638. doi: 10.1136/rmdopen-2017-000638Ogdie A, Palmer JL, Greenberg J, et al. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. J Rheumatol. 2019. doi: 10.3899/jrheum.171034Ogdie A, Palmer JL, Greenberg J, et al. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. J Rheumatol. 2019. doi: 10.3899/jrheum.171034Harrold LR, Stolshek BS, Rebello S, et al. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity. J Rheumatol. 2018;45(1):78-82. doi: 10.3899/jrheum.161567Harrold LR, Stolshek BS, Rebello S, et al. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity. J Rheumatol. 2018;45(1):78-82. doi: 10.3899/jrheum.161567Solmaz D, Bakirci S, Kimyon G, et al. The impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res (Hoboken). 2019. doi: 10.1002/acr.23836Solmaz D, Bakirci S, Kimyon G, et al. The impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res (Hoboken). 2019. doi: 10.1002/acr.23836Üreyen S, Solmaz D, Al Asoimi N, et al. Minimal disease activity in real life in psoriatic arthritis. Ann Rheum Dis. 2018;77:1600.Üreyen S, Solmaz D, Al Asoimi N, et al. Minimal disease activity in real life in psoriatic arthritis. Ann Rheum Dis. 2018;77:1600.Üreyen S, Solmaz D, Kimyon G, et al. Geographical differences in psoriatic arthritis: a transatlantic comparison. Ann Rheum Dis. 2018;77:1042. doi: 10.1136/annrheumdis-2018-eular.2728Üreyen S, Solmaz D, Kimyon G, et al. Geographical differences in psoriatic arthritis: a transatlantic comparison. Ann Rheum Dis. 2018;77:1042. doi: 10.1136/annrheumdis-2018-eular.2728Geijer M, Lindqvist U, Husmark T, et al. The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis.J Rheumatol. 2015;42(11):2110-7. doi: 10.3899/jrheum.150165Geijer M, Lindqvist U, Husmark T, et al. The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis.J Rheumatol. 2015;42(11):2110-7. doi: 10.3899/jrheum.150165Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407-13. doi: 10.1136/annrheumdis-2012-201972Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407-13. doi: 10.1136/annrheumdis-2012-201972Lindqvist U, Husmark T, Alenius G, et al. Treatment in mono-/oligo- and polyarthritic patients; a study on the swedish early psoriatic arthritis cohort (SWEPSA). Ann Rheum Dis. 2013;71:692-3. doi: 10.1136/annrheumdis-2012-eular.949Lindqvist U, Husmark T, Alenius G, et al. Treatment in mono-/oligo- and polyarthritic patients; a study on the swedish early psoriatic arthritis cohort (SWEPSA). Ann Rheum Dis. 2013;71:692-3. doi: 10.1136/annrheumdis-2012-eular.949Queiro R, Laiz A, Montilla-Morales CA, et al. Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology [abstract]. Arthritis Rheum. 2017;69 Suppl 10.Queiro R, Laiz A, Montilla-Morales CA, et al. Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology [abstract]. Arthritis Rheum. 2017;69 Suppl 10.Queiro R, Alonso AL, Park H, et al. Differences in the phenotypic expression of recent onset psoriatic arthritis among men and women: baseline data from the reapser study. Ann Rheum Dis. 2017;76:1333.Queiro R, Alonso AL, Park H, et al. Differences in the phenotypic expression of recent onset psoriatic arthritis among men and women: baseline data from the reapser study. Ann Rheum Dis. 2017;76:1333.Schneeweiss M, Merola JF, Karlson EW, et al. Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). BMC Dermatol. 2017;17(1):11. doi: 10.1186/s12895-017-0063-8Schneeweiss M, Merola JF, Karlson EW, et al. Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). BMC Dermatol. 2017;17(1):11. doi: 10.1186/s12895-017-0063-8Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S205-7.Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S205-7.Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor αtherapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382-90. doi: 10.1002/art.30117Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor αtherapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382-90. doi: 10.1002/art.30117Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor αinhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65(5):1213-23. doi: 10.1002/art.37876Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor αinhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65(5):1213-23. doi: 10.1002/art.37876Hojgaard P, Glintborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2015;74(12):2130-6. doi: 10.1136/annrheumdis-2014-205389. Epub 2014 Jul 25.Hojgaard P, Glintborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2015;74(12):2130-6. doi: 10.1136/annrheumdis-2014-205389. Epub 2014 Jul 25.Hojgaard P, Ballegaard C, Cordtz R, et al. Gender differences in biologic treatment outcomes – a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology (Oxford). 2018;1;57(9):1651-60. doi: 10.1093/rheumatology/key140Hojgaard P, Ballegaard C, Cordtz R, et al. Gender differences in biologic treatment outcomes – a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology (Oxford). 2018;1;57(9):1651-60. doi: 10.1093/rheumatology/key140Ballegaard C, Hojgaard P, Dreyer L, et al. Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2018;70(4):592-9. doi: 10.1002/acr.23333Ballegaard C, Hojgaard P, Dreyer L, et al. Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2018;70(4):592-9. doi: 10.1002/acr.23333Hojgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-αinhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016;55(12):2191-9. doi: 10.1093/rheumatology/kew326Hojgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-αinhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016;55(12):2191-9. doi: 10.1093/rheumatology/kew326Nissen CB, Horslev-Petersen K, Primdahl J. Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. Rheumatol Int. 2017;37(1):113-20. doi: 10.1007/s00296-016-3614-0Nissen CB, Horslev-Petersen K, Primdahl J. Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. Rheumatol Int. 2017;37(1):113-20. doi: 10.1007/s00296-016-3614-0Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO register. Ann Rheum Dis. 2017;76(1):105-11. doi: 10.1136/annrheumdis-2016-209270Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO register. Ann Rheum Dis. 2017;76(1):105-11. doi: 10.1136/annrheumdis-2016-209270Wervers K, Luime JJ, Tchetverikov I, et al. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis. Arthritis Res Ther. 2019;21(1):25. doi: 10.1186/s13075-019-1811-4Wervers K, Luime JJ, Tchetverikov I, et al. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis. Arthritis Res Ther. 2019;21(1):25. doi: 10.1186/s13075-019-1811-4Carmona L, de la Vega M, Ranza R, et al. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-163-7.Carmona L, de la Vega M, Ranza R, et al. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-163-7.Busquets N, Tomero E, Descalzo MA, et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford). 2011;50(11):1999-2004. doi: 10.1093/rheumatology/ker281Busquets N, Tomero E, Descalzo MA, et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford). 2011;50(11):1999-2004. doi: 10.1093/rheumatology/ker281Carmona L, Gomez-Reino JJ; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8(3):R72 doi: 10.1186/ar1941Carmona L, Gomez-Reino JJ; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8(3):R72 doi: 10.1186/ar1941Cruz Fernandez-Espartero M, Perez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2011;41(3):524-33. doi: 10.1016/j.semarthrit.2011.05.003Cruz Fernandez-Espartero M, Perez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2011;41(3):524-33. doi: 10.1016/j.semarthrit.2011.05.003Hernandez MV, Sanmarti R, Canete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013;65(12):2024-31. doi: 10.1002/acr.22096Hernandez MV, Sanmarti R, Canete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013;65(12):2024-31. doi: 10.1002/acr.22096Perez-Sola MJ, Torre-Cisneros J, Perez-Zafrilla B, et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137(12):533-40. doi: 10.1016/j.medcli.2010.11.032Perez-Sola MJ, Torre-Cisneros J, Perez-Zafrilla B, et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137(12):533-40. doi: 10.1016/j.medcli.2010.11.032Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum. 2011;41(1):71-80. doi: 10.1016/j.semarthrit.2010.08.005Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum. 2011;41(1):71-80. doi: 10.1016/j.semarthrit.2010.08.005Kalyoncu U, Kiraz S, Apras Bilgen S, et al. Psaid-12 can be used to determine the anti-TNF treatment decision in the psoriatic arthritis registry. Ann Rheum Dis. 2018;77:1601-2. doi: 10.1136/annrheumdis-2018-eular.5155Kalyoncu U, Kiraz S, Apras Bilgen S, et al. Psaid-12 can be used to determine the anti-TNF treatment decision in the psoriatic arthritis registry. Ann Rheum Dis. 2018;77:1601-2. doi: 10.1136/annrheumdis-2018-eular.5155Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49(4):697-705. doi: 10.1093/rheumatology/kep423Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49(4):697-705. doi: 10.1093/rheumatology/kep423Saad AA, Ashcroft DM, Watson KD, et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken). 2010;62(3):345-53. doi: 10.1002/acr.20104Saad AA, Ashcroft DM, Watson KD, et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken). 2010;62(3):345-53. doi: 10.1002/acr.20104Fagerli KM, Kearsley-Fleet L, Watson KD, et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open. 2018;4(1):e000596. doi: 10.1136/rmdopen-2017-000596Fagerli KM, Kearsley-Fleet L, Watson KD, et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open. 2018;4(1):e000596. doi: 10.1136/rmdopen-2017-000596Verstappen SM, Watson KD, Lunt M, et al. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49(8):1570-7. doi: 10.1093/rheumatology/keq131Verstappen SM, Watson KD, Lunt M, et al. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49(8):1570-7. doi: 10.1093/rheumatology/keq131Poole CD, Lebmeier M, Ara R, et al. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology (Oxford). 2010;49(10):1949-56. doi: 10.1093/rheumatology/keq182Poole CD, Lebmeier M, Ara R, et al. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology (Oxford). 2010;49(10):1949-56. doi: 10.1093/rheumatology/keq182

The authors declare that there are no conflicts of interest present.